Summary
30.54 0.57(1.89%)11/01/2024
ATS Corporation (ATS)
ATS Corporation (ATS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.89 | 0.27 | 2.29 | -24.16 | -9.67 | 0.00 | 0.00 | -24.89 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 30.54 | |
| Open | 29.94 | |
| High | 30.79 | |
| Low | 29.94 | |
| Volume | 43,807 | |
| Change | 0.57 | |
| Change % | 1.89 | |
| Avg Volume (20 Days) | 132,019 | |
| Volume/Avg Volume (20 Days) Ratio | 0.33 | |
| 52 Week Range | 0.00 - 0.00 | |
| Price vs 52 Week High | inf% | |
| Price vs 52 Week Low | inf% | |
| Range | 1.51 | |
| Gap Up/Down | -0.25 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,954 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
10/30 11:07 EST - zacks.com
Analysts Estimate ATS (ATS) to Report a Decline in Earnings: What to Look Out for
ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate ATS (ATS) to Report a Decline in Earnings: What to Look Out for
ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10/29 17:00 EST - businesswire.com
ATS To Host Second Quarter Earnings Call Wednesday November 6, 2024, at 8:30 a.m. Eastern
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the second quarter ended September 29, 2024, before markets open on Wednesday November 6, 2024. At 8:30 a.m. eastern November 6, 2024, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/775172.
ATS To Host Second Quarter Earnings Call Wednesday November 6, 2024, at 8:30 a.m. Eastern
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the second quarter ended September 29, 2024, before markets open on Wednesday November 6, 2024. At 8:30 a.m. eastern November 6, 2024, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/775172.
10/16 17:00 EST - businesswire.com
ATS to Participate in the Baird 2024 Global Industrial Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Baird 2024 Global Industrial Conference in Chicago on November 12, 2024. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Baird representative or dgalison@atsautomation.com. About ATS Corporation ATS Corporatio.
ATS to Participate in the Baird 2024 Global Industrial Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Baird 2024 Global Industrial Conference in Chicago on November 12, 2024. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Baird representative or dgalison@atsautomation.com. About ATS Corporation ATS Corporatio.
10/16 17:00 EST - businesswire.com
ATS to Participate in the Scotiabank Transportation & Industrials Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Scotiabank Transportation & Industrials Conference in Toronto on November 13, 2024. ATS is scheduled to host a fireside chat at the event at 2:00 p.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomat.
ATS to Participate in the Scotiabank Transportation & Industrials Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Scotiabank Transportation & Industrials Conference in Toronto on November 13, 2024. ATS is scheduled to host a fireside chat at the event at 2:00 p.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomat.
10/04 06:41 EST - zacks.com
New Strong Sell Stocks for October 4th
ATS, AZUL and BBC have been added to the Zacks Rank #5 (Strong Sell) List on October 4, 2024.
New Strong Sell Stocks for October 4th
ATS, AZUL and BBC have been added to the Zacks Rank #5 (Strong Sell) List on October 4, 2024.
09/30 05:35 EST - zacks.com
New Strong Sell Stocks for September 30th
ATS, AZUL and BW have been added to the Zacks Rank #5 (Strong Sell) List on September 30, 2024.
New Strong Sell Stocks for September 30th
ATS, AZUL and BW have been added to the Zacks Rank #5 (Strong Sell) List on September 30, 2024.
09/26 10:12 EST - seekingalpha.com
ATS Corporation: Diamond In The Rough
ATS provides vertically integrated automation solutions, focusing on Life Sciences and F&B sectors, with a robust backlog and strategic acquisitions enhancing growth potential. The macroeconomic environment, including lower interest rates and demographic changes, supports ATS's growth, especially in reshoring economies and increasing efficiency demands. Despite a healthy balance sheet, ATS faces risks from supply chain issues and cyclical industry exposure, with upcoming restructuring costs impacting short-term performance.
ATS Corporation: Diamond In The Rough
ATS provides vertically integrated automation solutions, focusing on Life Sciences and F&B sectors, with a robust backlog and strategic acquisitions enhancing growth potential. The macroeconomic environment, including lower interest rates and demographic changes, supports ATS's growth, especially in reshoring economies and increasing efficiency demands. Despite a healthy balance sheet, ATS faces risks from supply chain issues and cyclical industry exposure, with upcoming restructuring costs impacting short-term performance.
09/13 06:15 EST - zacks.com
New Strong Sell Stocks for September 13th
ATS, BMTX and B have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2024.
New Strong Sell Stocks for September 13th
ATS, BMTX and B have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2024.
08/19 17:00 EST - businesswire.com
ATS to Participate in the Jefferies Industrials Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Jefferies Industrials Conference in New York City, NY on September 5, 2024. ATS is scheduled to host a fireside chat at the event at 2:30 p.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.com/ in.
ATS to Participate in the Jefferies Industrials Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Jefferies Industrials Conference in New York City, NY on September 5, 2024. ATS is scheduled to host a fireside chat at the event at 2:30 p.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.com/ in.
08/19 16:38 EST - seekingalpha.com
ATS Corporation: This High-Quality Compounder Is A Bargain At 16x Earnings
ATS Corporation is a play on automation growth in manufacturing with exposure to electric vehicle battery outsourcing. The stock is down ~40% from its peak, but has potential for over 50% upside in a couple of years. Recent earnings show a slight EPS miss, but strong order bookings and backlog growth in non-transportation segments.
ATS Corporation: This High-Quality Compounder Is A Bargain At 16x Earnings
ATS Corporation is a play on automation growth in manufacturing with exposure to electric vehicle battery outsourcing. The stock is down ~40% from its peak, but has potential for over 50% upside in a couple of years. Recent earnings show a slight EPS miss, but strong order bookings and backlog growth in non-transportation segments.
08/13 10:35 EST - seekingalpha.com
ATS Corporation: Near Record Bookings In Q3 (Rating Upgrade)
ATS Corporation is a developer of automation technology with global operations and $3 billion in annual sales. Recent results showed a decline in revenue but strong performance in life sciences, with a record backlog of $990 million. Despite short-term challenges, ATS's strategic investments in life sciences and attractive valuation make it a compelling investment opportunity.
ATS Corporation: Near Record Bookings In Q3 (Rating Upgrade)
ATS Corporation is a developer of automation technology with global operations and $3 billion in annual sales. Recent results showed a decline in revenue but strong performance in life sciences, with a record backlog of $990 million. Despite short-term challenges, ATS's strategic investments in life sciences and attractive valuation make it a compelling investment opportunity.
08/10 14:55 EST - seekingalpha.com
ATS Corporation (ATS) Q1 2025 Earnings Call Transcript
ATS Corporation (NYSE:ATS ) Q1 2025 Results Conference Call August 8, 2024 8:30 AM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants Michael Glen - Raymond James Patrick Sullivan - TD Cowen Joe Ritchie - Goldman Sachs Justin Keywood - Stifel Maxim Sytchev - National Bank Financial David Ocampo - Cormark Securities Patrick Baumann - JPMorgan Operator Hello, everyone, and welcome to the ATS Corporation First Quarter Conference Call and Webcast. This call is being recorded on August 8, 2024 at 8:30 a.m.
ATS Corporation (ATS) Q1 2025 Earnings Call Transcript
ATS Corporation (NYSE:ATS ) Q1 2025 Results Conference Call August 8, 2024 8:30 AM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants Michael Glen - Raymond James Patrick Sullivan - TD Cowen Joe Ritchie - Goldman Sachs Justin Keywood - Stifel Maxim Sytchev - National Bank Financial David Ocampo - Cormark Securities Patrick Baumann - JPMorgan Operator Hello, everyone, and welcome to the ATS Corporation First Quarter Conference Call and Webcast. This call is being recorded on August 8, 2024 at 8:30 a.m.
08/08 08:16 EST - zacks.com
ATS (ATS) Lags Q1 Earnings Estimates
ATS (ATS) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.51 per share a year ago.
ATS (ATS) Lags Q1 Earnings Estimates
ATS (ATS) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.51 per share a year ago.
08/01 11:06 EST - zacks.com
Earnings Preview: ATS (ATS) Q1 Earnings Expected to Decline
ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: ATS (ATS) Q1 Earnings Expected to Decline
ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/22 06:45 EST - businesswire.com
ATS Announces Dates of First Quarter Results Conference Call and Annual Meeting of Shareholders
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the first quarter ended June 30, 2024, before markets open on Thursday August 8, 2024. At 8:30 a.m. eastern August 8, 2024, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/283321487, and th.
ATS Announces Dates of First Quarter Results Conference Call and Annual Meeting of Shareholders
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the first quarter ended June 30, 2024, before markets open on Thursday August 8, 2024. At 8:30 a.m. eastern August 8, 2024, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/283321487, and th.
05/23 07:00 EST - globenewswire.com
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), presented positive results from its Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus following administration of Neumifil. These data were featured during an oral presentation* at the American Thoracic Society (ATS) in San Diego on 21st May.
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), presented positive results from its Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus following administration of Neumifil. These data were featured during an oral presentation* at the American Thoracic Society (ATS) in San Diego on 21st May.
05/22 11:20 EST - globenewswire.com
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting
05/21 14:30 EST - globenewswire.com
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego.
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego.
05/20 14:15 EST - globenewswire.com
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
05/20 14:15 EST - globenewswire.com
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024.
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024.